KOSDAQBiotech & Pharma068760

Celltrion Pharm

₩40,550▼ 1.10%2026-11-18 close
Market Cap
₩1.8T
Turnover
₩2.5B
Volume
60K
Shares out.
44.4M
PER
37.1×
PBR
3.8×
EPS
₩1,112
Dividend Yield
0.48%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩200 per share · Prices as of the 2026-11-18 close

01

Report overview

Celltrion Pharm: Quarterly Profit Gains Rest on CMO and Bio Volume

Revenue and operating profit rose for two straight quarters through Q3 2026, but the share price sits at a high level relative to recent earnings, so whether profit growth continues is the key item to track.

  1. 1

    Revenue in 2025 was KRW 536.4 billion and operating profit was KRW 56.1 billion, the largest year in the 2022-2025 period. The operating margin recovered from 7.8% in 2024 to 10.5% in 2025.

  2. 2

    Q3 2026 revenue was KRW 161.9 billion and operating profit was KRW 23.9 billion, a 14.8% operating margin. Revenue and operating profit have increased for two consecutive quarters since Q2 2026.

  3. 3

    The CMO segment booked Q3 2026 revenue of KRW 48.2 billion, up 26.2% year on year, with PFS commercial production revenue of KRW 40.4 billion, up 44.2%.

  4. 4

    Yuflyma 40mg PFS-S launched in Korea after national health insurance reimbursement listing on November 1, 2026, and a 20mg PFS version is planned for 2027.

  5. 5

    The debt-to-equity ratio at year-end 2025 was 74.2%, the highest in the 2022-2025 period. Market capitalization is large relative to the KRW 49.1 billion of controlling-shareholder net income over the last four quarters.

02

Business structure

Celltrion Pharm's business is organized into three segments: chemical drugs, biologics, and contract manufacturing (CMO).

In Q3 2026 the chemical segment booked KRW 68.4 billion, led by the liver-related product Dexes at KRW 17.7 billion (up 10.3% year on year) and the hypertension drug Dilatrend at KRW 15.8 billion (up 5.5%).

The biologics lineup includes the autoimmune drug Remsima at KRW 14.9 billion (up 18.8%), the blood cancer drugs Truxima, Herzuma and Vegzelma, the bone drug Stoboclo at KRW 7.7 billion (up 64.5%), and the eye drug Idenzelt at KRW 4.1 billion (up 149.1%).

Biologics revenue was KRW 33.4 billion in Q1 2026 (up 60.1%) and KRW 36.6 billion in Q2 2026 (up 12.5%), so growth varied by quarter. The CMO segment recorded KRW 48.2 billion in Q3 2026, up 26.2%, of which PFS commercial production was KRW 40.4 billion, up 44.2%.

On a Q3 2026 basis, chemical drugs account for roughly 42% of revenue and CMO for roughly 30%. The model combines sales of its own products with manufacturing for other drugmakers, and both have grown together.

In contract manufacturing the company competes with large CMO operators that have PFS production capacity, and management said it runs PFS lines at maximum utilization. The pen-type Remsima received approval for a higher dosage, which supported sales. Stecima and Aptoma each booked KRW 0.5 billion in Q3 2026 as they entered the market.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩138.2B₩16.1B11.7%
2025Q4₩154.4B₩13.7B8.9%
2026Q1₩132.1B₩12.9B9.8%
2026Q2₩153.3B₩19.3B12.6%
2026Q3₩161.9B₩23.9B14.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩386B₩38.2B₩26B9.9%7.3%68.1%
2023₩388.8B₩36.1B₩21.3B9.3%5.6%70.3%
2024₩477.8B₩37.2B₩22B7.8%5.5%68.7%
2025₩536.4B₩56.1B₩38.8B10.5%8.9%74.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue rose from KRW 386 billion in 2022 to KRW 388.8 billion in 2023 (up 0.7%), KRW 477.8 billion in 2024 (up 22.9%) and KRW 536.4 billion in 2025 (up 12.3%), an increase for three consecutive years from 2023 to 2025. 2025 was the largest revenue year in the 2022-2025 period.

Operating profit fell from KRW 38.2 billion in 2022 to KRW 36.1 billion in 2023 (down 5.5%), then rose to KRW 37.2 billion in 2024 (up 3.2%) and KRW 56.1 billion in 2025 (up 50.7%), two consecutive years of growth.

Operating profit growth in 2025 far outpaced revenue growth, which means the margin recovery drove the profit gain. The operating margin was 9.9% in 2022, 9.3% in 2023, 7.8% in 2024 and 10.5% in 2025, the highest of the four years except that 2022 is slightly lower.

Net income attributable to controlling shareholders was KRW 26 billion in 2022, KRW 21.3 billion in 2023 (down 18.1%), KRW 22 billion in 2024 (up 3.3%) and KRW 38.8 billion in 2025 (up 76.4%). Net income including non-controlling interests is reported at the same values for each year.

Quarterly, revenue went from KRW 138.2 billion in Q3 2025 to KRW 154.4 billion in Q4 2025 (up 11.7%) and then fell to KRW 132.1 billion in Q1 2026 (down 14.4%), with operating profit at KRW 12.9 billion in that quarter.

Biologics (KRW 33.4 billion, up 60.1%) and CMO (KRW 33.6 billion, up 22%) grew year on year in Q1 2026. Revenue then rose to KRW 153.3 billion in Q2 2026 and KRW 161.9 billion in Q3 2026, with operating profit of KRW 19.3 billion and KRW 23.9 billion, two consecutive quarters of growth.

The Q3 2026 operating margin was 14.8%, and the company attributed the improvement to a lower cost ratio relative to sales. Controlling-shareholder net income over the last four quarters totaled KRW 49.1 billion.

Operating cash flow moved from -KRW 4.05 billion in 2022 to KRW 8.76 billion in 2023, KRW 56.6 billion in 2024 and KRW 86.4 billion in 2025.

Total equity at year-end 2025 was KRW 436 billion, all attributable to controlling shareholders, total liabilities were KRW 323.5 billion, and the debt-to-equity ratio was 74.2%, the highest of the four years.

05

Industry analysis

In biosimilars, revenue depends on how quickly prescribing hospitals expand after launch. In Q1 2026 the company attributed biologics growth to new prescriptions at major hospitals, and in Q3 it again cited expanding biologic prescriptions as a driver.

In its Q2 2026 release it said it would widen market share for its main drugs in the second half. Contract manufacturing reflects global demand. In Q2 2026, CMO revenue reached KRW 49.7 billion, up 53.4% year on year, and PFS commercial production revenue reached KRW 35.3 billion, up 51.9%.

Because CMO profitability depends on how fully plants are used, sustaining maximum PFS line utilization is a key variable for the segment. Samsung Biologics is a large CMO peer, and the gap in facility scale and customer base is wide.

The chemical segment relies on long-established products such as Dexes and Dilatrend, which are growing at a moderate 5-10% pace. If price competition in biosimilars intensifies, price competitiveness will shape both sales volume and margins at once.

Pricing the new 40mg PFS-S product at the lowest level among 40mg products with the same ingredient reflects that competitive environment.

06

Outlook

In its Q3 2026 release the company said it would carry the quarter's segment growth through year-end and aim for meaningful annual results. It stated a direction rather than numeric targets.

On the new-product side, Yuflyma 40mg PFS-S launched in Korea after national health insurance reimbursement listing on November 1, 2026. It adds a PFS-S format to the existing pen type, with a safety feature that covers the needle after injection.

The company plans a 20mg PFS version in 2027 to complete a Korean lineup matching the original product's strength and format. In its Q2 2026 release it said it would widen market share for its main drugs in the second half, and in Q1 2026 it set out a plan to expand PFS-centered contract manufacturing capacity.

The growth potential of the CMO segment depends on PFS line utilization and the pace of new contracts. Price competitiveness can support prescription growth but may also compress per-product margins, so both effects need to be read together.

The confirmable schedule includes the close of fiscal 2026 at year-end, the 2026 annual report filing, and the preliminary annual results expected in early 2027.

07

Valuation

PER
37.1×
PBR
3.8×
ROE
11.0%
EPS
₩1,112
BPS
₩10,763
Dividend per share
₩200

Measured against controlling-shareholder net income of KRW 49.1 billion over the last four quarters, market capitalization is large, so the share price sits at a high level relative to current earnings. Relative to book value, the market value carries a large premium over net assets.

The dividend yield is low relative to the share price, and any change in dividend policy is a shareholder-return item to watch. Over several years, controlling-shareholder net income rose for two consecutive years after the 2023 low, and quarterly profit has recovered through Q3 2026.

Operating cash flow improved from negative in 2022 to KRW 86.4 billion in 2025, which strengthened cash backing for earnings. At the same time the debt-to-equity ratio rose to 74.2%.

Multiples move with the pace at which quarterly profit accumulates, so the same share price reads differently depending on whether profit growth holds.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Back-to-back quarterly gains

Revenue fell quarter on quarter in Q1 2026, but revenue and operating profit rose in both Q2 and Q3. Q3 operating profit of KRW 23.9 billion was up 48.4% year on year. The operating margin of 14.8% improved 3.1 percentage points, and the company attributed this to a lower cost ratio relative to sales.

Higher PFS line utilization

Q3 2026 CMO revenue was KRW 48.2 billion, up 26.2%, and PFS commercial production revenue was KRW 40.4 billion, up 44.2%. The company said its PFS lines are running at maximum utilization. At high utilization, fixed costs are spread over more sales, which lifts the margin.

Expanding new-product lineup

Yuflyma 40mg PFS-S was listed for national health insurance reimbursement and launched on November 1, 2026, priced at the lowest level among 40mg products with the same ingredient. A 20mg PFS version is planned for 2027 to match the original's strength and format in Korea. Stecima and Aptoma each booked KRW 0.5 billion in Q3 2026 as they began sales.

09

Bear factors

Quarterly earnings volatility

Q1 2026 revenue of KRW 132.1 billion fell 14.4% quarter on quarter, and operating profit fell 6.0%. Operating profit also fell 14.8% in Q4 2025 from the prior quarter. Consecutive quarterly growth covers only two quarters since Q2 2026, so the trend is short.

Slow growth in chemical drugs

Chemical segment revenue in Q3 2026 was KRW 68.4 billion, with Dexes up 10.3% and Dilatrend up 5.5%. Chemical revenue growth in Q1 2026 was also 5.5%. Much of the growth depends on biologics and CMO, so slower prescriptions or contracts in those two segments would lower overall growth.

Leverage and valuation level

The debt-to-equity ratio at year-end 2025 was 74.2%, the highest in 2022-2025. Operating cash flow improved, but debt relative to equity rose. Market value carries a large premium to net assets, and current multiples are high relative to recent controlling-shareholder net income.

10

Risk factors

Earnings volatility

Quarterly revenue swung, including a 14.4% quarter-on-quarter drop in Q1 2026, and the annual operating margin fell to 7.8% in 2024. Whether the margin recovery in 2025 and Q3 2026 holds across more quarters remains to be seen. Growth rates differ by segment, so a slowdown in one segment can flow directly into the total.

Financial structure

At year-end 2025, total liabilities were KRW 323.5 billion, total equity was KRW 436 billion, and the debt-to-equity ratio was 74.2%, up from 68.1% in 2022. If capacity expansion or borrowing continues, financial burden could increase, so the debt mix and investment plans should be checked in future annual reports.

Pricing and competition

The new Yuflyma 40mg PFS-S was priced at the lowest level among 40mg products with the same ingredient. If price competition intensifies, per-product margins could fall even as sales grow. The CMO segment also faces competition from large CMO operators, so plant utilization and contract terms will shape results.

11

What to watch next

  1. Late December 2026

    The company said Q3 growth would carry through year-end. Whether Q4 2026 revenue and operating profit hold near Q3 levels is the item to check.

  2. Early 2027 (estimated from prior release timing)

    The preliminary full-year 2026 results are due. It will show whether the annual operating margin holds near the 10.5% recorded in 2025.

  3. By late March 2027

    This is the filing deadline for the 2026 annual report. Debt composition, segment revenue mix and CMO capacity investment plans will be disclosed there.

  4. 2027

    Checks whether the planned 20mg PFS version of Yuflyma launches on schedule. The key question is how prescription trends after launch feed into biologics revenue.

  5. Around early May 2027 (estimated from prior Q1 release)

    Q1 2027 preliminary results are due. It will show whether quarterly revenue declines like Q1 2026 recur.

12

Overall view

Celltrion Pharm's revenue rose for three consecutive years from 2023 to 2025, and operating profit grew 50.7% to KRW 56.1 billion in 2025, broadening the earnings base. After a Q1 2026 revenue decline, revenue and operating profit rose for two consecutive quarters in Q2 and Q3, and the Q3 operating margin was 14.8%.

Growth drivers are PFS-based contract manufacturing, expanding biosimilar prescriptions, and the Yuflyma 40mg PFS-S launched in November 2026. On the other side, growth in the core chemical products has been moderate at roughly 5-10%, and the debt-to-equity ratio at year-end 2025 was 74.2%, the highest since 2022.

The share price sits at a high level relative to KRW 49.1 billion of controlling-shareholder net income over the last four quarters, so whether profit growth continues matters more. Strengths and weaknesses should be weighed equally, and the balance will become clearer in upcoming filings.

The next checkpoints are the 2026 annual report and the preliminary 2027 full-year and Q1 results. This report is for information only and does not include a buy or sell opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. view.asiae.co.kr
  2. celltrionph.com
  3. pointe.co.kr
  4. m.news.nate.com
  5. thefairnews.co.kr
  6. celltrionph.com
  7. nnewss.com
  8. monews.co.kr
  9. insightkorea.co.kr
  10. medigatenews.com
  11. fnnews.com
  12. dev.re.kr
  13. hankyung.com
  14. newspim.com
  15. newspim.com
  16. hankyung.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis